drugset / Trial / NCT03379974

Exercise Versus DDAVP in Patients With Mild Hemophilia A

NCT03379974 ↗

RandomizedCrossoverOpen-labelTreatment

Summary

Individuals with mild hemophilia A (MHA) bleed infrequently but can in the setting of trauma which often is when participating in sports/exercise. Although both exercise and DDAVP (desmopressin) can raise Factor 8/Von Willebrand Factor (FVIII/VWF levels), it is not clear whether the pathophysiological mechanism is the same. Consequently it is not known if DDAVP and exercise would have additive effects in raising FVIII:C and VWF levels or if one would one negate the effect of the other. The aim of this 2 center (Sickkids and Nationwide Children's), prospective, cross-over design study is to compare the impact of exercise vs. DDAVP on hemostasis in patients with MHA and also to investigate the impact of sequentially administering these interventions on their hemostatic indices.

Timeline

Start
2018-07-31
Primary completion
2019-08-30
Completion
2019-12-05

Drugs

EvaluationDrugModalityDoseRoute
Subject 1-desamino-8-Darginine vasopressin Unknown 150 ug Intranasal
Subject 1-desamino-8-Darginine vasopressin Unknown 300 ug Intranasal

Indications